Purified Recombinant VP2 Protein Can Provide Complete Protection to very Virulent Infectious Bursal Disease Virus Challenge as a Subunit Vaccine

Background: The very virulent infectious bursal disease virus has become the dominant path type that damage lymphoid tissues with high mortality in young chickens in China. Current commercial vaccines are modified live vaccines originated from classic form of virulent virus and cannot provide complete protection as they cause bursal atrophy and immunosuppression. There is an urgent call to develop more effective and safer vaccines.